Live Markets
Wednesday, July 29, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
13F HOLDINGS REPORT

Atlas Venture Life Science Advisors, LLC

Quarter ended Q2 2024 · Filed August 9, 2024 · Accession 0001104659-24-087431

Total Value
$949.6M
Positions
15
Other Managers
0
Confidential Omitted
No
View on SEC.gov

Holdings (15)

#IssuerTicker / CUSIPSharesValue% of Filing
1Dyne Therapeutics, Inc.DYN8,020,136$283.0M29.80%
2Kymera Therapeutics, Inc.KYMR5,350,422$159.7M16.82%
3Third Harmonic Bio, Inc.88427A10710,907,859$141.8M14.93%
4Disc Medicine, Inc.IRON2,509,456$113.1M11.91%
5Day One Biopharmaceuticals, Inc.DAWN6,430,257$88.6M9.33%
6Korro Bio, Inc.KRRO1,137,149$38.5M4.06%
7Q32 Bio, Inc.QTTB2,092,106$37.6M3.95%
8Generation Bio, Co.37148K1008,279,484$23.3M2.46%
9Vigil Neuroscience, Inc.92673K1085,836,874$23.3M2.46%
10Replimune Group, Inc.REPL2,098,300$18.9M1.99%
11Ikena Oncology, Inc.45175G1085,018,178$8.3M0.87%
12Tectonic Therapeutics, Inc.TECX378,447$6.2M0.66%
13Dianthus Therapeutics, Inc.DNTH136,979$3.5M0.37%
14Aerovate Therapeutics, Inc.0080641071,799,232$3.0M0.31%
15Spero Therapeutics, Inc.SPRO535,336$695,9370.07%